Hot Topic From RxSchool
OTC Transdermal Oxybutynin Patch
April 1, 2014
Overactive bladder (OAB) is a condition that affects an estimated 33 million Americans, the majority of whom are older women. Although overactive bladder is a treatable medical condition, more than 80% of women with this condition do not seek out medical attention. Trandermal oxybutynin, Oxytrol® For Women is the first OTC agent for OAB approved by the FDA for women ages 18 years and older. Oxytrol® is available as a patch that is applied to the skin every 4 days. The patch delivers 3.9 milligrams of oxybutynin per day. Oxybutynin is an anticholinergic agent that works to relax the bladder muscle.
The FDA approval of the prescription to OTC switch was based on data from several well-designed studies that demonstrated a woman's ability to correctly recognize OAB symptoms, understand key safety measures on the label, judge if the product is right or wrong for her, and appropriately uses Oxytrol® For Women in an unsupervised setting. The FDA is considering this a partial switch due to the product still requiring a prescription for men with overactive bladder. When combined with daily lifestyle modifications, women saw a reduction of urinary accidents due to OAB by 75% vs. 50% with placebo. Oxytrol® For Women patches are clear and thin, making them discreet and undetectable under ordinary clothing. Side effects include itching, rash or redness where patch is applied. Sleepiness, dizziness and blurry vision may also occur. Alcohol may enhance these effects. Sine this product is now sold and marketed OTC, pharmacists are likely to receive more questions about OAB & this product. It is important to remind women to combine the use this drug with pelvic floor muscle strengthening, such as Kegel exercises.
About OXYTROL Oxybutynin Transdermal System | OXYTROL for Women. Retrieved from: http://www.oxytrolforwomen.com
FDA approvers over-the-counter Oxytrol for Women to treat overactive bladder. Retrieved from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm336815.htm
News Topics
Top News Articles
- New Parkinson's Disease Drug Approved
May 4, 2017 - Hypertension Guidelines Consensus Statement
April 1, 2017 - Novel Abuse-Deterrent Morphine Approved
March 1, 2017 - New Heart Failure Guidelines
February 1, 2017 - New Eczema Drug Approved
January 1, 2017